SPECIAL EDITION: BoB@JPMElixirgen Therapeutics CEO Akihiro Ko joins the Business of Biotech for the final  episode in our special series recorded at JPM Week in San Francico. Life Science Leader Chief Editor Ben Comer joined us for the conversation. We dive deep into Elixirgen's unique, temperature-controlled in-vivo gene expression technology designed to address common cell therapy administration challenges and unwanted, off-target immunogenicity effects. Ko also shares progress on the company's ex-vivo candidate EXG-34217,  an autologous cell therapy for telomere biology disorders, offers his take on the ever-crowded RNA therapeutics space and how the company is separating itself from the crowd, and much more!Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!